Close

Novavax (NVAX) Reports RSV F Vaccine Phase 3 Missed Primary, Secondary Efficacy Objectives

Go back to Novavax (NVAX) Reports RSV F Vaccine Phase 3 Missed Primary, Secondary Efficacy Objectives

Novavax Announces Topline RSV F Vaccine Data from Two Clinical Trials in Older Adults

September 15, 2016 4:18 PM EDT

Topline data from the Resolve Phase 3 trial did not meet pre-specified efficacy objectives The attack rate for the Phase 3 primary objective was approximately 25% of that observed in Phase 2 trial  Topline data from our Phase 2 rollover trial suggest improved vaccine efficacy from a second year of dosing

Management will host a conference call at 5:00 pm ET time today

GAITHERSBURG, Md., Sept. 15, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq: NVAX) today announced topline data from two clinical... More